Komori
Linical (2183) · FactSettlement-related expenses continue to be recognized

Payment of a Settlement Amount Relating to Transactions with Customers

First written in FY2021-Q3. . Latest entry: FY2022-Q3.

4entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2021-Q3 – FY2022-Q32021: 320212022: 12022
Same theme, other companies
Extraordinary Loss from Settlement PaymentA theme 29 companies write about · 29 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2019: 1 of 6 companies on the "Worse" side.

4 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 29 companies compared. The sentences above are computed from all 29.
Full recordFilings, disclosures and news, newest first
  1. FY2022-Q3Settlement-related expenses continue to be recognizedAnnual report

    「In addition, profit attributable to owners of the parent amounted to ¥524 million, up 234.1% year on year, as legal fees and settlement amounts related to arbitration concerning projects undertaken by Accelovance, Inc., the predecessor of Linical Accelovance America, Inc. (LAA), before its acquisition, as well as costs related to measures taken in response to the cyberattack, were incurred, while the Company entered into a settlement agreement concerning disputes arising from indemnification provisions and other clauses of the merger agreement with the seller of LAA and received settlement proceeds from escrow.」

    While payments of legal fees and settlement amounts related to arbitration continued, settlement proceeds were received in the dispute with the seller, resulting in profit attributable to owners of the parent of ¥524 million.
  2. FY2022-Q2Settlement amounts and legal fees continue to be recognizedAnnual report

    「Settlement amounts, legal fees and other costs incurred in connection with arbitration proceedings between Linical Accelovance America, Inc., a consolidated subsidiary of the Company, and Topical Remedy, LLC and other parties, as well as settlements between the parties, have been recognized as arbitration-related expenses.」

    Settlement amounts, legal fees and other costs of ¥108.045 million related to arbitration proceedings and settlements were recognized as arbitration-related expenses.
  3. FY2021Disclosure of the full-year settlement amount recognizedAnnual report

    「Consolidated fiscal year (from 1 April 2020 to 31 March 2021) Settlement amount 133,166」

    Settlement amounts of ¥133.166 million paid in transactions with customers were recognized as an extraordinary loss for the full fiscal year.
  4. FY2021-Q3First statedAnnual report

    「This represents settlement amounts paid in transactions with customers.」

    Settlement amounts of ¥134.630 million related to transactions with customers were recognized as an extraordinary loss in the nine-month period of the current fiscal year.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Linical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Payment of a Settlement Amount Relating to Transactions with Customers | Linical Co.,Ltd. (2183) | Komori